Printer Friendly

Actinium Pharmaceuticals appoints Robert Daly VP, head of clinical operations.

Actinium Pharmaceuticals (ATNM) announced the appointment of Robert Daly, M.S., Ph.D., to the position of Vice President, Head of Clinical Operations, effective immediately. In this role, Dr. Daly will oversee all clinical operations, with a focus on executing Actinium's progressing pivotal Phase 3 trial for Iomab-B as a targeted conditioning agent, driving forward the Company's growing CD33 program including its advancement in targeted conditioning, as well as future clinical trial expansion for the entire pipeline. He will be supervised by Dr. Mark Berger, Actinium's CMO and will report to Actinium's Chairman and CEO, Sandesh Seth, for strategic and organizational related matters. Prior to joining Actinium, Dr. Daly served as Vice President, Clinical, at CTI BioPharma (CTIC).

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Sep 6, 2018
Previous Article:Talend appoints Adam Meister CFO.
Next Article:KB Home enters Smart Home partnership with Google.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters